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Exposure Assessment of Pharmaceuticals and Their Metabolites in the 1 
Aquatic Environment: Application to the French Situation and Preliminary 2 
Prioritization 3 
                                               Besse, J.P., Kausch Barreto, C., Garric, J. 4 
 5 
ABSTRACT 6 
 7 
Low levels of pharmaceuticals have been detected in many countries in surface waters. As 8 
a wide range of pharmaceuticals can reach aquatic environments, a selection of molecules to 9 
survey is the first step before implementing a monitoring program. We used a simple equation to 10 
calculate Predicted Environmental Concentrations (PECs), adapted from the European Medicine 11 
Agency model used for the Environmental Risk Assessment (ERA) of human pharmaceutical. 12 
Excretion fractions for pharmaceuticals were determined for 76 compounds. Using year 2004 13 
French drug consumption data, we determined aquatic PECs for 112 parent molecules and 14 
several metabolites. Considering excretion fractions of pharmaceuticals can lead to drastically 15 
reduce predicted concentrations reaching the aquatic environment and help to target 16 
environmentally relevant pharmaceuticals and metabolites. Calculated PECs using the described 17 
methodology are consistent with French field measurements. The simple model for calculating 18 
PECs can be used as a valuable estimation of the exposure. Risk quotient ratios were also 19 
calculated. Due to the lack of ecotoxicological data, the use of PEC/PNEC ratios is not enough 20 
informative to prioritize pharmaceuticals likely to pose a risk for surface waters. Alternative ways 21 
to prioritize risk to pharmaceuticals, combining PEC, pharmacological, and ecotoxicological data 22 
available from the literature, should be implemented.  23 
 24 
INTRODUCTION 25 
 26 
It is now recognized that pharmaceutical compounds reach the environment and can be 27 
considered as environmental contaminants. A wide range of drugs including antibiotics, 28 
antidepressants, non steroidal anti-inflammatories (NSAIDs), blood lipid-lowering agents, anti-29 
epileptics, and β-blockers have been found in wastewater effluents and surface waters of several 30 
countries (Halling-Sorensen et al. 1998; Ternes 1998; Kümmerer 2000; Kolpin et al. 2002). 31 
These observations have contributed to a growing interest in targeting and quantifying these 32 
substances in terrestrial and aquatic environments. In France, there is a concern for monitoring 33 
pharmaceuticals in freshwaters as this country shows the highest consumption of pharmaceutical 34 
drugs in Europe (DREES 2006). This concern is addressed in the framework of the French Plan 35 
National Santé Environnement (PNSE 2004) and in Europe, in the context of preventing 36 
deterioration and protecting and enhancing the status of aquatic ecosystems, within the European 37 
Water Framework Directive. River basin authorities therefore need to establish a list of priority 38 
pharmaceuticals prior to implementing a comprehensive survey in surface waters. In this aim, we 39 
developed a prioritization approach to identify human pharmaceuticals to be monitored in French 40 
surface waters. As a first step in this prioritization strategy, we used a simple equation to 41 
calculate Predicted Environmental Concentrations (PECs) adapted from the model proposed by 42 
the European Medicine Agency (EMEA) guideline (EMEA 2006). This equation takes into 43 
account three main parameters: the amount of active ingredients consumed by the population 44 
over a year, the removal fraction in wastewater treatment plants (WWTPs), and the excretion 45 
fraction of the active molecule. Pharmaceuticals enter surface waters mainly from WWTPs 46 
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(Kümmerer 2000, 2001; Bound and Voulvoulis 2004). The majority of human pharmaceuticals 47 
probably reach surface waters after being excreted from the body, either as parent compounds or 48 
metabolites. Consequently, we reviewed metabolism data in order to estimate values of the 49 
excreted fraction of pharmaceuticals. We also targeted metabolites that present significant 50 
pharmacological activity and can be found in the environment in non-negligible concentrations. 51 
Our study focused on the most widely used human pharmaceuticals in France. We excluded 52 
steroid estrogens from this work, as the risk of endocrine disruption has been previously 53 
discussed (Langston et al. 2005; Mills and Chichester 2005; Fent et al. 2006). Cytotoxic 54 
compounds were also excluded because these drugs have specific toxic properties (mutagenesis 55 
and carcinogenicity), and need to be assessed in a specific prioritization approach. PECs for 56 
parent compounds and metabolites were calculated using the methodology presented here and 57 
were compared with field measurements. Next, the reliability of the applied methodology was 58 
discussed. Finally, we determined risk quotient ratios, according to the EMEA guideline. Results 59 
and use of the PEC/PNEC (Predicted No Effect Concentration) risk quotient for prioritizing and 60 
ranking pharmaceuticals are discussed. 61 
 62 
I. MATERIALS AND METHODS 63 
 64 
I.1. Model Used for Calculating PECs 65 
 66 
The EMEA guideline (EMEA 2006) proposes an approach to estimate PEC values for 67 
pharmaceuticals in surface water. PECs are calculated by using the following general equation: 68 
 69 
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where PEC is expressed in mg·l−1 using the following parameters: consumption is the quantity 73 
(mg·year−1) of an active molecule consumed by the population during 1 year in a defined zone 74 
(generally a country); hab is the number of inhabitants and 100 the correction factor for the 75 
percentages; 365 is the number of days per year (day·year−1); DOSEai: maximum recommended 76 
daily dose of an active molecule consumed per inhabitant (mg. inhabitants−1 day−1); DDD: 77 
Defined Daily Dose for an active molecule (mg. inhabitants−1 day−1); WWinhab: volume of 78 
wastewater per person per day (default value = 200 l. inhabitants−1 day−1); CAPstp: capacity of 79 
local sewage treatment plant (inhabitants); dilution is the dilution factor from WWTP effluent to 80 
surface waters (default value set to 10). Factor stands for the fraction of the molecule adsorbed to 81 
the suspended matter; Fpen (%): market penetration factor; Fpen is the proportion of the 82 
population being treated daily with a specific drug substance; Fexcreta: excretion fraction of the 83 
active molecule; Fstp: fraction of emission of the drug from wastewater treatment plants 84 
(WWTP) directed to surface water, Fstp can be defined as (1-WWTP removal fraction). 85 
Combination of Eqs. (1), (2), and (3) gives the following: 86 
 87 
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 89 
In the aim of our prioritization strategy, we simplified this last equation. Eq. (4) is finally 90 
transformed into Eq. (5) as follows: 91 
 92 
365×××
××
=
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 94 
all PEC calculations presented in this study will refer to Eq. (5). 95 
 96 
I.2. Consumption Data Sources 97 
 98 
The French medicine agency (Agence Française de Sécurité Sanitaire des Produits de 99 
Santé, AFSSAPS, Paris) kindly shared yearly sales data compulsory provided by the 100 
pharmaceutical firms to AFSSAPS. These data cover both sale quantities of all prescribed drugs 101 
delivered in France and over-the-counter drugs for the year 2004 for hospitals and pharmacies. In 102 
the scope of this work we assume that delivered quantities represent quantities effectively 103 
consumed by the French population and that the consumed amount was evenly distributed 104 
throughout the year, as assumed in Carlsson et al. (2006). The candidate list of pharmaceuticals 105 
was established as follows: a first set of molecules was selected from the top 100 pharmaceuticals 106 
used in France (AFSSAPS 2006). To this first set of molecules, we added those that were 107 
reported in previous studies to be detected in the aquatic environment or to be of high aquatic 108 
ecotoxicity, and finally the molecules known to be persistent in the environment. The list of 109 
selected molecules is displayed in Table 1; compounds are sorted by decreasing consumption. As 110 
discussed in the introduction, neither steroid estrogens nor cytotoxics were included in this set of 111 
molecules. 112 
 113 
I.3. Determination of the Parameter Fexcreta 114 
 115 
Implications of Pharmaceutical Metabolism for Environmental Considerations 116 
 117 
In the human body, active molecules pass through several biotransformation mechanisms 118 
ending in their elimination from the organism. Schematically, biotransformations can be 119 
summarized into two different steps: phase I and phase II biotransformations. Phase I metabolites 120 
can show a pharmacological activity similar or not to the parent compound and be biologically 121 
active. As an example, norfluoxetine, a phase I metabolite of the serotoninergic antidepressant 122 
fluoxetine, shows the same pharmacological activity as the parent compound. Phase II 123 
metabolites are phase I metabolite or parent compound conjugated with a functional group (such 124 
as glucuronide, sulphate, or acetate), which enhance elimination from the organism and inactivate 125 
the molecule. It has been shown for estrogens that glucuronide phase II metabolites could be 126 
cleaved in the environment and thus regenerate the parent compound (Ternes et al. 1999; 127 
D’Ascenzo et al. 2003). Moreover, sulphate conjugates appear to be more stable in the 128 
environment (D’Ascenzo et al. 2003). As shown for estrogens, we can reasonably assume that 129 
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glucuronide conjugates of pharmaceutical compounds are subjected to the same degradation 130 
pathway and are cleaved in the environment. Therefore, active metabolites and glucuronide 131 
conjugates have to be considered in an Environmental Risk Assessment (ERA) or a prioritization 132 
approach. 133 
 134 
Fexcreta Calculation 135 
 136 
To provide reasonable Fexcreta values, we made the following assumptions: We assumed 137 
that all glucuronide conjugates are cleaved in the environment. Consequently, Fexcreta was 138 
determined by summing the excreted proportion of the unchanged active molecule (in urine 139 
and/or in feces) and the proportion of the parent molecule existing as a glucuronide conjugate. If 140 
no information was given on the nature of the conjugate, we assumed a worst case hypothesis 141 
considering that all conjugates were glucuronide conjugates. Rates of molecule not absorbed by 142 
the digestive tract were added to the other excretion rates to give the final Fexcreta value. 143 
Modifications in metabolism rates that can occur in unhealthy people were not taken into 144 
account. When more than one excretion value was given, we always chose the greater one, 145 
assuming a worst case scenario (decimal values were rounded up or down to the nearest value). 146 
When information such as “negligible excretion of unchanged drug” was given with no other 147 
specific information, we assumed a Fexcreta value minimum of 0.01. When no reliable data were 148 
found, no Fexcreta value was calculated. Finally, when data were available, we calculated the 149 
Fexcreta value for active metabolites using the same methodology with the assumptions 150 
described earlier. The methodology used to determine Fexcreta values is synthesized in Figure 1. 151 
 152 
I.4. Reference Books and Databases Reviewed 153 
 154 
In order to determine metabolism pathways of selected pharmaceuticals and to calculate 155 
Fexcreta values, we reviewed data from several sources commonly used by healthcare services 156 
(hospitals, pharmacovigilance services, pharmacists, etc.): the Banque Claude Bernard (BCB 157 
2006), a complete and free French databank on human pharmaceuticals (http://www.resip.fr), the 158 
BCB is updated monthly, notably with data from the Marketing Authorisation Application 159 
(MAA); the BIAM database (www.biam2.org 2006); the drug database drugs.com 160 
(www.drugs.com); the Micromedex Drugdex_R databank (from Thomson Micromedex, 161 
available at www.micromedex.com/products/drugdex); the Martindale compendium’s Complete 162 
Drug Reference (Martindale 2002); the Goodman & Gilman’s The Pharmacological Basis of 163 
Therapeutic (Hardman et al. 1996); the Merck Index (Merck 2001); and the Dorosz Guide 164 
pratique des m´edicaments (Dorosz 2007). The HSDB database (http://www.toxnet. 165 
nlm.nih.gov/) was also investigated. 166 
 167 
 168 
II. RESULTS 169 
 170 
II.1. Excretion Factor Values 171 
 172 
Excretion factor values are displayed in Table 1. Reviewing the databases allowed us to 173 
determine Fexcreta values for 76 molecules of the 112 selected. From the 76 compounds for 174 
which Fexcreta values were determined, 45 showed excretion rates less than 0.5 and 23 175 
compounds present excretion rates less than 0.1. Although the data determined here are consistent 176 
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with previous published excretion rates, some differences can be noted for a few of the 177 
compounds studied. We report an excretion value for sulfamethoxazole of 0.4 compared to 0.15 178 
(Ternes 1998) and 0.25 versus 0.01–0.08 for ibuprofen (Ternes 1998). In the case of ibuprofen, 179 
this difference can be explained by the fact that the proportion of glucuronide conjugates was 180 
added in our study. For furosemide, in taking into account the glucuronide ester metabolites, we 181 
calculated a Fexcreta value of 1 instead of the value of 0.4 reported by Bindschedler et al. (1997). 182 
As the glucuronide ester is reported to be the only significant metabolite of furosemide 183 
(Micromedex Drugdex_R 2006), we considered that all furosemide was excreted unchanged or as 184 
glucuronide metabolite, with 100% of the dose excreted in the environment after cleavage of the 185 
ester. Hirsch et al. (1999) reported excretion fractions for antibiotics. Our results are in good 186 
agreement with these values for doxycycline, amoxicillin, trimethoprim, and erythromycin; for 187 
erythromycin, we assumed a worst case value of 1. On the contrary, for roxithromycin and 188 
clarithromycin, the results differ significantly. Hirsch reports excretion rates of both unchanged 189 
molecules greater than 0.6, whereas we determined a 0.5 value for roxithromycin and a 0.3 value 190 
for clarithromycin. For carbamazepine, a Fexcreta of about 0.01 to 0.03 was reviewed from the 191 
literature (Ternes 1998; Jjemba 2006), which corresponds to the unchanged fraction excreted in 192 
urine. However, carbamazepine is also excreted in faeces and can be metabolized in glucuronide 193 
conjugates (Lynn et al. 1978; BCB; Micromedex Drugdex 2006). Nevertheless, as no 194 
quantitative data were available to allow calculating an accurate Fexcreta value, we chose to 195 
consider Fexcreta for this molecule as undetermined rather than giving a wrong estimation. For 196 
the active metabolite of simvastatin (β-hydroxy-acid metabolite), we did not find any value in the 197 
reviewed databases. However, Carlsson et al. (2006) report that 55% of the parent pro-drug 198 
simvastatin is excreted under the activated form. Therefore, we assumed a Fexcreta value of 0.55 199 
for the β-hydroxy-acid metabolite in our work. 200 
 201 
II.2. Active Metabolites Entering the Aquatic Environment 202 
 
203 
Reviewing metabolism pathways of pharmaceutical compounds allowed us to target 204 
specific metabolites that may be of potential concern for the aquatic environment. These 205 
metabolites were selected because they present either a significant pharmacological activity, or a 206 
significant excretion fraction (≥0.1, threshold value assumed by the EMEA). Metabolites of 207 
interest are listed with their excretion values and their pharmacological properties in Table 2. In 208 
addition, searching for active metabolites allowed us to highlight specific compounds that are 209 
both active molecules and metabolites. Two important drugs exemplify this particular profile: 210 
oxazepam and prednisolone. Oxazepam is an anxiolytic drug belonging to the benzodiazepine 211 
class.  212 
 213 
Oxazepam shows a very particular profile because it is both an active molecule and a 214 
metabolite of the following active molecules: prazepam, diazepam, nordazepam, and clorazepate 215 
dipotassium (Figure 2). Prazepam, diazepam, and clorazepate are metabolized in humans to 216 
desmethyldiazepam, an active metabolite also used as a drug (nordazepam), which is 217 
subsequently transformed to oxazepam. Oxazepam then undergoes direct glucuronidation before 218 
its excretion. Glucuronide conjugates of oxazepam should then undergo subsequent cleavage in 219 
the environment and then regenerate the active oxazepam. This case is interesting because 220 
diazepam, the benzodiazepine commonly searched for in the aquatic environment, is not expected 221 
to reach surface waters in significant concentrations. Diazepam was detected at low frequency in 222 
German WWTP effluents with a maximum concentration of 40 ng·l−1(Ternes 1998), at very low 223 
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concentration in surface waters, less than 5 ng·l−1(Fent et al. 2006) and once in drinking waters 224 
at level up to 10 ng·l−1(Waggott et al. 1981, cited by Halling-Sorensen 1998). Nevertheless, 225 
most of the studies did not detect diazepam in effluents (Clara et al. 2005; Carballa et al. 2005; 226 
Rabiet et al. 2006) or in surface waters (Ternes 1998; Zuccato et al. 2005). On the contrary, 227 
oxazepam, which is potentially excreted up to 100% (taking into account the glucuronide 228 
conjugates) of the dose absorbed for the five different active molecules, is expected to be present 229 
at greater levels in the aquatic environment. A very recent study on occurrence of 230 
pharmaceuticals in aquatic systems in France (Togola et al. 2007) did not detect diazepam in 231 
surface waters, whereas oxazepam was measured at significant concentrations (up to 1500 232 
ng·l−1). Therefore, we assume that oxazepam is the benzodiazepine to search for in the 233 
environment, and that this drug could be used as an indicator of contamination of the aquatic 234 
environment by benzodiazepines.  235 
 236 
Prednisolone belongs to the glucocorticoid therapeutic class. Glucocorticoids are natural 237 
(hydrocortisone or cortisol) or synthesized (prednisolone, prednisone, 238 
betamethasone, or dexamethasone) steroid compounds. They present immunosuppressant 239 
properties and are used in many different pathologies (inflammation, allergy, auto-immune 240 
disease, etc.). Reviewed metabolism data are incomplete but available data show that only a small 241 
portion (less than 5%) of glucocorticoids are excreted in unchanged form (Schorderet 1998), 242 
except for prednisolone, which is excreted in a greater fraction: up to 24% in case of a large dose 243 
(Schorderet 1998; Martindale 2002). Prednisolone is also the active form of prednisone. 244 
Therefore, non-negligible levels of prednisolone can reach the environment. Consequently, 245 
prednisolone should be searched for in the environment and could be used as a marker of 246 
contamination for other glucocorticoids. This assumption is partially confirmed by the results of 247 
Chang et al. (2007), who report that prednisolone is the synthetic glucocorticoid frequently found 248 
in surface waters. These results indicate that metabolism data are useful for selecting relevant 249 
pharmaceuticals or metabolites to survey in surface waters. 250 
 251 
II.3. Calculated PECs for Parent Compounds 252 
 253 
PECs were calculated using Eq. (5). As all required data were not available (especially 254 
WWTP removal rates data) for all the selected molecules, three PEC values were calculated 255 
corresponding to varying conservative levels. PECA is the conservative PEC calculated with 256 
actual amounts of pharmaceuticals and not refined by Fexcreta and Fstp values. PECB are PECA 257 
refined by Fexcreta values. PECC are PECBrefined by Fstp values. Results for PECA and PECB 258 
are displayed in Table 1. Considering PECA values, only 15 compounds show a value greater 259 
than 1 µg·l−1 and our results highlight paracetamol, ibuprofen, dextropropoxyphene, amoxicillin, 260 
and aspirin. PECA values of troxerutin and diosmin, two flavonoid compounds with vitamin P 261 
properties (used against veinous insufficiency of the lower limbs), are also in the top 10 because 262 
they are widely prescribed in France, contrary to other European countries; these last two drugs 263 
may be specific to the French consumption profile. 264 
 265 
For compounds such as sertraline, dextropropoxyphene, omeprazole, and pantoprazole, 266 
the PECB values are drastically reduced. For example, for the antidepressant sertraline, PECA is 267 
equal to 142 ng·l−1 but drops to 20 ng·l−1 when excretion rates are taken into account. 268 
Comparison of PECA and PECB values confirms that metabolism is one of the most important 269 
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processes that can reduce the quantity of parent pharmaceuticals reaching the aquatic 270 
environment.  271 
 272 
Therefore, metabolism data and excretion rates have to be taken into account in PEC 273 
calculation (Huschek et al. 2004). As data on metabolism rates are currently available through 274 
databases, they can help to prioritize pharmaceuticals of greater concern.  275 
 276 
II.4. Comparison of PEC Values with Field Measurements 277 
 278 
WWTP removal rates data are limited. Reviewing literature data, we found only data for 279 
24 molecules by the 111 selected in this work (Table 3); some of them show a high variability, 280 
depending on the study. This is especially the case for metoprolol and diclofenac with removal 281 
fractions varying from less than 0.1 to 0.83 and from less than 0.1 to 0.75, respectively. 282 
Considering the heterogeneity of data, we determined PECC values by two methods. First, we 283 
calculated extreme PECC values by taking into account the minimal and maximal WWTP 284 
removal rates reviewed. Second, we calculated a refined PECC using theWWTP removal rates 285 
reported by Paffoni et al. (2006), as this study provides data for almost all 24 compounds. Our 286 
first objective was to compare PEC values for surface water with field measurements, but, as only 287 
few measurements of pharmaceuticals in French surface waters are available, we used data on 288 
occurrence in WWTP effluents. Consequently, in order to compare the calculated PEC with real 289 
measurements, we used Eq. (5) without the default dilution factor of 10. Calculated PECC for 290 
WWTP effluents with WWTP effluents measurements performed in France are compared in 291 
Table 4. 292 
 293 
Calculated PECs for pharmaceuticals appear to correlate well with effluents 294 
measurements. This is the case for diclofenac, ibuprofen, naproxen, ketoprofen, bezafibrate, 295 
metoprolol, and propranolol. As a general rule, calculated PECs for antibiotics were in the range 296 
but slightly greater than the measured concentrations in effluents. For two compounds, however, 297 
PECs are very different from the effluent measurements (more than one order of magnitude); this 298 
is the case for amoxicillin and doxycycline. For amoxicillin, the difference could be explained by 299 
the fact that this molecule is rapidly degraded in water, which has been previously suggested 300 
(Zuccato et al. 2005). Another β-lactam, piperacillin, showing a PECB value for WWTP effluent 301 
of about 1µg·l−1 has been searched for but not detected in WWTP effluents or surface waters in 302 
the French aquatic environment (Paffoni et al. 2006). These results suggest that β-lactam 303 
antibiotics may undergo rapid environmental degradation but this hypothesis must be confirmed. 304 
For doxycycline, previous studies have reported that tetracyclines should be bound to suspended 305 
matter and sediment due to their complexing properties (Hirsch et al. 1999). Therefore 306 
doxycycline is unlikely to be found under dissolved form but could still be in the water column if 307 
bound to suspended materials, especially colloids. 308 
 309 
PECBs of diazepam and simvastatin (a prodrug) are very low (2 ng·l−1) and therefore 310 
those molecules were not expected to be found in effluents or surface waters, which is confirmed 311 
by field measurements (Paffoni et al. 2006; Rabiet et al. 2006). We also investigated PEC values 312 
in surface water for a few metabolites of potential concern (Table 5), considering excretion rates 313 
of metabolites and consumed amounts of the respective parent compound. Only a few of the 314 
metabolites considered in this work have already been measured in aquatic environments (but not 315 
in France), which allowed us to compare PEC and field measurements. The calculated PECB for 316 
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acetylsulfamethoxazole is in the range of the measured concentrations reported in WWTP 317 
effluents and surface waters downstream from a WWTP (Ashton et al. 2004).  318 
 319 
The anti-inflammatory drug ibuprofen can generate two main metabolites: carboxy and 320 
hydroxy-ibuprofen. Our calculated PECC values reported here are consistent with field 321 
measurements for the two metabolites, if we consider a WWTP removal fraction of 0.95 for the 322 
two compounds (Bendz et al. 2005). The PECC value of fenofibric acid calculated with 323 
aWWTPremoval fraction of 0.82 (Paffoni et al. 2006) is in the range of the surface water levels 324 
reported by Paffoni (Table 5). For other metabolites, no field data were available to allow any 325 
comparison; the following active metabolites—hydroxymetronidazole, norpropoxyphene, and 326 
demethyltramadol (excreted from metronidazole, dextropropoxyphene, and tramadol, 327 
respectively)—show PECB values for surface waters of approximately 250 ng·l−1. For oxazepam 328 
(benzodiazepine), a final PECB value was calculated by summing the PECs of different sources 329 
of oxazepam, which reached roughly 200 ng·l−1. Recent field measurements (Togola et al. 2007) 330 
reported an average concentration of oxazepam in surface water of about 200 ng·l−1, which is in 331 
good agreement with our calculated PEC. 332 
 333 
II.5. Calculation of Risk Quotients and Risk Assessment for Pharmaceuticals 334 
 335 
As a first attempt to prioritize pharmaceuticals, we calculated risk quotient ratios. 336 
According to the EMEA guideline (EMEA 2006), PNECs are calculated using assessment 337 
factors, as described in the European Technical Guidance Document (TGD 2003). Unlike TGD, 338 
the EMEA guideline enforces the use of chronic toxicity data and requires long-term NOEC for 339 
the base set (i.e ., three NOEC values from three different trophic levels, applying an assessment 340 
factor of 10 to the lowest value). The review of available ecotoxicity data showed that only six 341 
compounds bring together the conditions required by the EMEA guideline: clofibric acid, 342 
propranolol, carbamazepine, sulfamethoxazole, fluoxetine, and diclofenac. If we do not use only 343 
the EMEA guideline but also refer to the European TGD (2003) for pharmaceuticals with limited 344 
chronic data (1 or 2 NOECs from different trophic levels), it is then possible to calculate PNEC 345 
values and PEC/PNEC quotients for a further 16 compounds. 346 
 347 
As all data required for calculating PECC values for pharmaceuticals were not always 348 
available, we used PECB values for furosemide, sertraline, paroxetine, citalopram, and fluoxetine 349 
and PECA values for carbamazepine, aspirin, and fluvoxamine. Results are displayed in Table 6. 350 
All risk quotients are less than one, except for amoxicillin, which presents a very high ratio of 62, 351 
suggesting a risk for the aquatic environment. Nevertheless, a number of pharmaceuticals show a 352 
risk quotient close to 1. This is the case for propranolol, ofloxacin, and erythromycin. For these 353 
molecules, a risk cannot be ruled out. 354 
 355 
Three other molecules showed a risk ratio near 1, carbamazepine, sertraline, and 356 
furosemide. However, calculated PEC for carbamazepine is conservative and PNEC values for 357 
the two other compounds were calculated with an assessment factor of 100; therefore risk ratio is 358 
overestimated. Although reported to be one of the most toxic compounds, the serotoninergic 359 
antidepressant fluoxetine shows a low PEC/PNEC ratio, due to the very low PEC of 9 ng·l−1 360 
calculated for this molecule. 361 
 362 
 363 
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III. DISCUSSION 364 
 365 
III.1. Reliability of the PEC Calculation, Uncertainties, and Flaws 366 
 367 
Although field measurements are available for a limited number of pharmaceuticals, preliminary 368 
results indicate that PEC calculation is in accordance with environmental levels for 369 
pharmaceuticals. Therefore, the simple equation proposed here is valuable for predicting aquatic 370 
concentrations for pharmaceuticals in any country. Previously published works on exposure 371 
assessment of pharmaceuticals came to the same conclusion. Bound and Voulvoulis (2006) used 372 
EMEA guidelines to calculate PEC values and compared them with their own field 373 
measurements. They concluded that PEC calculation using the EMEA model could provide 374 
useful information for the prioritization of pharmaceuticals. The same conclusion was drawn by 375 
Liebig et al. (2006), who quoted that even if the EMEA model does not reflect the complexity of 376 
the real environment, it permits calculating PECs in accordance with field measurements. This 377 
study also reported that the factor with the highest impact and uncertainty was the production 378 
volume, estimated in the EMEA model in using Fpen and DOSEai. Using actual amounts of 379 
consumption, as in this study, and Fexcreta values give a reliable exposure assessment for 380 
pharmaceuticals. 381 
 382 
Nevertheless, some uncertainties remain in the model we used. PEC values were 383 
calculated based on human consumption data during 1 year. As some pharmaceutical compounds 384 
are used both in human and veterinary medicine, there are still uncertainties about the actual 385 
amounts of pharmaceuticals reaching surface waters. This is particularly the case for antibiotic 386 
and antiprotozoal compounds. Theoretically, including veterinary consumption is likely to ensure 387 
a more comprehensive PEC. However, as the routes of administration and ways of reaching the 388 
aquatic environment differ between veterinary and human pharmaceuticals, this study only 389 
focused on human use. 390 
 391 
Another major uncertainty remains on the quantity actually consumed by patients. Data 392 
provided by the AFSSAPS give information on the quantities delivered in hospitals and 393 
pharmacies per year but cannot give any information on the patient compliance. Patients’ non-394 
compliance can be quite large, and quantities actually consumed by people may be less than the 395 
quantities delivered, especially for drugs that do not require medical prescription as NSAIDs. 396 
Moreover, if data shared by the AFSSAPS provided a complete profile of the national annual 397 
consumption, no data were available regarding local consumptions of pharmaceuticals, which are 398 
likely to differ from one region to another. Finally, temporal variations of consumption 399 
(especially for pharmaceuticals used in acute treatments, such as antibiotics), and of quantities 400 
reaching the aquatic environment cannot be taken into account. Uncertainties also lie in the 401 
parameter Fstp: review of available data shows a high heterogeneity in removal rates. 402 
Moreover,WWTP efficiency toward pharmaceuticals can be influenced by the season (Castiglioni 403 
et al. 2006), therefore leading to varying surface water concentrations throughout the year. 404 
 405 
At last, great uncertainties lie in the default values proposed by the model. For example, 406 
the default value for quantities of effluent is set to 200 l·inhab−1·day−1, which is a mean value 407 
that can be accepted at the national scale in France. However, for some specific French regions, 408 
this value may drop to 150 l·inhab−1·day−1. Using this last value in our calculation significantly 409 
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increases PEC values by 25%. To this extent, PEC values calculated for the WWTP effluents are 410 
more reliable than surface water PECs. 411 
 412 
Equation (5) does not take into account the fraction of the molecule sorbed to sediment or 413 
suspended matter, which is a flaw in the proposed model. The EMEA model (Eq. [1]) includes 414 
this factor (FACTOR), but its calculation requires Koc values that are very scarce at the moment. 415 
In addition, Eq. (5) does not take into account abiotic and biotic degradation processes that can 416 
occur in surface waters. Abiotic processes are reported to be most important ones (Fent et al. 417 
2006). Photolysis and hydrolysis were suggested to be rapid ways of removal of amoxicillin in 418 
the environment (Andreozzi et al. 2004). This statement was supported by the fact that 419 
amoxicillin was only detected in surface waters at low levels (Zuccato et al. 2005; Paffoni et al. 420 
2006). The β-blocker propranolol was reported to be rapidly photodegraded and therefore is not 421 
expected to be persistent in surface waters (Qin-Tao and Williams 2007). Nevertheless, 422 
calculated PEC for propranolol was in the range of field measurements. This could be partially 423 
explained by the fact that propranolol and most of the pharmaceuticals are continuously released 424 
in the environment. This fact could balance the degradation processes in the environment, 425 
therefore some authors have suggested that pharmaceuticals should be considered as “pseudo-426 
persistent” contaminants due to this continuous release (Daughton and Ternes 1999). 427 
 428 
III.2. Relevance of Fexcreta Values 429 
 430 
As excretion rates range from 0.1 to 1, they are to be taken into account in a prioritization 431 
or a risk assessment approach. Metabolism of pharmaceuticals is one of the first steps that limit 432 
the concentrations reaching the environment. Consequently, it is valuable to review such data and 433 
to search for the most accurate excretion values that would allow us to calculate more realistic 434 
PECs. 435 
 436 
In this work, two main assumptions were made in the determination of the Fexcreta 437 
values. First, we did not take into account modifications of metabolism than can occur in 438 
unhealthy people (specifically people with hepatic or renal impairment). As an example: chronic 439 
renal failure can result in a decrease in propranolol metabolism via downregulation of hepatic 440 
cytochrome P450 activity (www.drugs.com, 2006), therefore potentially leading to increase 441 
excretion of unchanged drug. However, as people affected by renal or hepatic impairment may 442 
only represent a small part of the population, we considered that the resulting variability of the 443 
excretion fractions can be neglected when calculating PEC for the aquatic environment. Accuracy 444 
of PECs with field measurements presented here seems to confirm this assumption. 445 
 446 
Second, we considered a worst case scenario for the Fexcreta values when more than one 447 
excretion fraction was given. This assumption, however, did not lead to high over-predictions of 448 
concentrations, as the variability of recovered values was limited and rarely exceeded 10%; 449 
contrary to WWTP removal fractions. Only 4 compounds of the 76 showed a greater variability: 450 
sotalol (excretion rates values between 0.66 and 0.9), clarithromycin (0.18 to 0.3), ranitidine (0.3 451 
to 0.5), and rifampicin for which excretion in urine is dose-dependant (Micromedex Drugdex_R 452 
2006). 453 
 454 
 455 
 456 
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III.3. Environmental Relevance of Active Metabolites 457 
 458 
The metabolites reviewed should not be all of environmental concern. However, as no 459 
data exist about the ecotoxicity of these compounds, it is rather difficult to draw any conclusions. 460 
Moreover, it is not clear that pharmacologically inactive metabolites will not have any biological 461 
effects or toxicity on aquatic non-target organisms, especially lower invertebrates. Nevertheless, 462 
we will make a few suggestions to select the metabolites to search for in surface waters: 463 
 464 
• The amount of the parent molecule consumed should be taken into account when 465 
selecting for relevant metabolites. 466 
• Active metabolites that are pharmacologically equipotent to the parent compound should 467 
be considered unless they are excreted at low rates. Because it is not possible to propose a 468 
threshold excretion value using available data (metabolism, occurrence, and ecotoxicity), 469 
we assume a threshold value of 10%, which is the value proposed by the EMEA (2006) to 470 
assess the relevance 471 
• of a metabolic fraction of a pharmaceutical compound. 472 
• Active metabolites showing a mechanism of action that is different from the parent 473 
compound should also be considered if their excretion fraction is equal to or greater than 474 
0.1. 475 
• Because there are no data on the toxicity of pharmacologically inactive metabolites on 476 
aquatic organisms, such metabolites should be considered on a case-by case approach 477 
considering the amount of parent compound and their excretion fraction. 478 
• Metabolites with an excretion fraction greater than the parent compound should be 479 
considered relevant for the aquatic environment. 480 
• Active metabolites of prodrugs should be searched for in the environment. 481 
 482 
Finally, it should be noted that no data are available on the potential toxicity of inactive 483 
metabolites, considering that the term “pharmacologically inactive metabolite” does not 484 
necessarily mean that such a metabolite has no effects on an aquatic organism. Considering these 485 
assumptions, we selected 30 environmentally relevant metabolites (Table 2) for which risk 486 
assessment should be implemented.  487 
 488 
Only human metabolites were considered in this work. However, other degradation products 489 
can be generated in the environment, especially by photolysis. Photodegradation metabolites can 490 
be more toxic than the parent compound (Della- Greca et al. 2004; Isidori et al. 2005, 2006); and 491 
attention should also be paid on such metabolites. 492 
 493 
III.4. Considerations on Risk Assessment for Pharmaceuticals 494 
 495 
As quoted by several authors (Jones et al. 2002; Carlsson et al. 2006; Fent et al. 2006), 496 
ecotoxicological data, and notably chronic data, are lacking and thus limit the outcome of ERA 497 
based on risk quotients. Relevant chronic data are needed. Preliminary results presented here can 498 
nevertheless give some insight on the risk assessment of pharmaceuticals. Antibiotics and notably 499 
amoxicillin could present a risk for the aquatic environment. However, two points must be noted 500 
for this molecule. First, the NOEC value used to derive the PNEC is based on growth inhibition 501 
testing on the cyanobacteria Synechococcus leopoliensis (Andreozzi et al. 2003). If other 502 
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available data on amoxicillin confirm that cyanobacteria seem very sensitive to amoxicillin 503 
(Holten-Lutzoft et al. 1999), data on green algae species (Holten-Lutzoft et al. 1999) and on 504 
invertebrates (Garric et al. 2006) only indicate limited toxicity. 505 
 506 
Second, previous studies seem to indicate that amoxicillin is rapidly degraded in the 507 
aquatic environment (Andreozzi et al. 2004; Zuccato et al. 2005). Consequently, the risk ratio for 508 
amoxicillin could be smaller than predicted here. Nevertheless, antibiotics remain one of the 509 
more hazardous pharmaceutical classes for the aquatic environment due to their antimicrobial 510 
activity. Among antibiotics, macrolides, which are not only toxic toward cyanobacteria but also 511 
toward green algae (Isidori et al. 2005), may represent a class of compounds of high concern for 512 
the aquatic environment. 513 
 514 
Although reported to be one of the most toxic compounds, the serotoninergic 515 
antidepressant fluoxetine shows a low PEC/PNEC ratio (0.09), due to the very low PEC of 9 516 
ng·l−1 calculated for this molecule. It should be noted that the active metabolite norfluoxetine, 517 
with similar pharmacological activity, may act additively with fluoxetine. It therefore seems 518 
reasonable to consider the sum of the two PEC values (fluoxetine + norfluoxetine) in the 519 
calculation of the risk quotient, which increases the fluoxetine risk quotient to 0.26, still less than 520 
1 but 3 times greater than the previous value. Metabolites should be considered when performing 521 
a pharmaceutical ERA, at least for PEC calculation. However, it is not yet possible to assess the 522 
hazard of these metabolites, due to the lack of ecotoxicity data. For metabolites that are reported 523 
to be equipotent (the same mechanism of action and pharmacological potency) to the parent 524 
compound, using the sum of respective PECs may be appropriate. For active metabolites with 525 
differences in pharmacological potency but with the same mechanism of action, it will be 526 
necessary to take their relative potency into account. For metabolites with a mechanism of action 527 
different from the parent compound, however, ecotoxicological data remain necessary to assess 528 
their toxicity.For non-pharmacologically active metabolites that may have toxic effects on 529 
aquatic organisms, it is also necessary to build ecotoxicological assays.  530 
 531 
Finally, in the context of an ERA, an effort should be made on the study of the effect of 532 
pharmaceuticals mixtures on aquatic organisms for several reasons. First, pharmaceuticals with 533 
the same mechanism of action may act additively on aquatic organisms (Cleuvers 2003; Fraysse 534 
and Garric 2005). Therefore, in a risk assessment framework, such pharmaceuticals should be 535 
considered together. As an example, for SSRIs, summed PECs of all parent compounds (and also 536 
active metabolites) should be taken into account rather than considering separate PECs; moreover 537 
the ecotoxicological effects of such mixtures should be better evaluated. 538 
 539 
Second, interactions between pharmaceuticals are well studied and taken into account in 540 
humans as the concomitant use of some pharmaceuticals can lead to severe consequences. 541 
Mixtures of pharmaceuticals known to interact with each other should be assessed for 542 
ecotoxicity. Third, a number of pharmaceuticals are cytochrome P450 enzyme modulators or 543 
Para-glycoprotein-P modulators (proteins that play a key role in the resistance to xenobiotics), 544 
and thus are likely to disrupt homeostasis of non-target organism and to increase their sensitivity 545 
to other pollutants (Endicoot and Ling 1989; Toomey and Epel 1993). Therefore, one of the 546 
major issues when considering concentrations entering the environment should be interactions 547 
between pharmaceuticals or between pharmaceuticals and other pollutants: single-compound 548 
assays are not sufficient to provide accurate environmental risk assessment of pharmaceuticals. 549 
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Nevertheless, except for a few laboratory (Cleuvers 2003; Eguchi et al. 2004; Fraysse and Garric 550 
2005; Chritensen et al. 2007), and microcosms studies (Brain et al. 2004; Richards et al. 2004) 551 
the ecotoxicological assays done to date only focus on single compounds. 552 
 553 
III.5. Considerations on the Prioritization of Pharmaceuticals 554 
 555 
Equation (5) can be used to assess the environmental exposure for pharmaceuticals. If all 556 
data were available, a preliminary prioritization based on PEC values could be conducted. 557 
However,WWTPremoval rates are scarce and limit such an approach. In addition, the effects are 558 
not taken into account, and such a simple approach does not allow to select the compounds 559 
showing the highest risk. To fill this lack and to provide an initial hazard assessment of 560 
pharmaceuticals, some authors have proposed the use of QSAR and a test battery based on 561 
mechanism of action (Escher et al. 2006; Lienert et al. 2007). 562 
 563 
We consider, as do several authors, that the use of existing pharmacological, 564 
toxicological, and pharmacokinetic data is likely to be helpful in assessing the risk of 565 
pharmaceuticals, as they could provide a better understanding of the fate and effect of 566 
pharmaceuticals in the aquatic environment ( Lange and Dietrich 2002; Seiler 2002; Fent et al. 567 
2006; Jjemba 2006). The use of mammalian pharmacological and toxicological data was 568 
proposed to help to prioritize the potential impacts of pharmaceuticals to fish (Huggett et al. 569 
2003). In practice, pharmacokinetic parameters such as bioavailability, half-life in the human 570 
body or excretion rates may be used as indicators of the environmental behaviour of 571 
pharmaceuticals in the aquatic environment. Jjemba (2006) suggested that compounds excreted 572 
unchanged in low amounts may also show low degradability in the environment. As the 573 
pharmacokinetic behavior is influenced by the same parameters that can modify environmental 574 
behavior such as pH and pKa, it makes sense to draw a parallel between pharmacokinetic and 575 
environmental criteria. Williams et al. (2006) very recently studied the correlation between the 576 
environmental partitioning coefficient Kd and the distribution volume Vd, which measures the 577 
distribution of a pharmaceutical within the body. These results suggest that pharmacokinetic 578 
parameters should be helpful to estimate environmental behavior for pharmaceuticals. Known 579 
side effects of pharmaceuticals may also be valuable to indicate potential harmful effects on non-580 
target organisms as it as already been shown for diclofenac in vultures (Oaks et al. 2004), and in 581 
fish (Schwaiger et al. 2004; Triebskorn et al. 2004). Taking into account such effects could make 582 
it possible to target the harmful impacts of these compounds, at least on non-target vertebrates. 583 
 584 
Comparative pharmacology could also be useful to understand toxicity pathways of 585 
pharmaceuticals. At the moment, studies have only considered the major mechanism of action 586 
(MoA) of pharmaceuticals in ecotoxicity assays. However, evidence shows that compounds 587 
belonging to same pharmacological and chemical classes (e.g., compounds with same 588 
mechanisms of action), can display a high variability in toxic values on same species and 589 
endpoints (Huggett et al. 2002; Henry et al. 2004; Dzialowski et al. 2006; Garric et al. 2006). 590 
Indeed, pharmaceuticals are not only characterized by their principal MoA but also by some 591 
additional pharmacological characteristics that should be taken into account. In the case of β-592 
blockers, several authors (e .g., Fraysse and Garric 2005; Fent et al. 2006) have suggested that 593 
differences in toxicity should be partially explained by pharmacological properties specific to 594 
these compounds such as receptor selectivity or membrane-stabilizing activity. For SSRIs, results 595 
from Henry et al. (2004) show that NOEC values on the reproduction of C. dubia range more 596 
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than two orders of magnitude. Pharmacological data indicate that even if SSRIs have a greater 597 
selectivity for blocking serotonin reuptake (their principal MoA), they also have affinities to 598 
some other receptors and reuptake inhibitor activities on other systems such as the noradrenergic 599 
or dopaminergic systems (Hyttel 1993; Dulin et al. 2002). Such “secondary” MoAs could help to 600 
understand toxic responses. Sertraline is both the most toxic SSRI on C. dubia reproduction 601 
(Henry et al. 2004) and the most potent inhibitor of serotonin reuptake (Hyttel 1993); however, it 602 
is not the most selective SSRI, as it also exerts an activity on dopamine and noradrenaline 603 
reuptake (Hyttel 1993). Citalopram, which is the less toxic SSRI (Henry et al. 2004), is not the 604 
less potent molecule but the most selective one. Such pharmacological data suggest that the toxic 605 
response observed for C. dubia could not only be linked to serotonin reuptake but also to other 606 
MoAs; this hypothesis remains to be confirmed.  607 
 608 
A prioritization methodology for pharmaceuticals could therefore cross PEC values with 609 
relevant pharmacological data, such as specific mechanism of action or relevant chronic adverse 610 
effects, to give a reliable estimation of the risk. Such a methodology should allow to bypass the 611 
lack of ecotoxicological data and could provide useful information for building ecotoxicological 612 
assays. 613 
 614 
CONCLUSION 615 
 616 
The main objective of this study was to assess the exposure concentration of 617 
pharmaceuticals in surface water with an emphasis on metabolites. The PEC calculation proposed 618 
here is reliable, as calculated PECs are in good agreement with field measurements. Metabolism 619 
data are important to take into account as they allow a more relevant selection of pharmaceuticals 620 
and metabolites to survey in aquatic ecosystems. Moreover, there is a need to consider the 621 
specificity of drugs consumption profile for each country, as such a specificity can lead to 622 
different priority compounds. Another objective was to perform a preliminary prioritization using 623 
risk quotients ratios. Given the lack of relevant ecotoxicological data, it was not possible to 624 
prioritize pharmaceuticals using risk ratios. As it will take time to build enough ecotoxicological 625 
data, we consider that the use of pharmacokinetic and pharmacological data can help to prioritize 626 
pharmaceuticals. Moreover, comparative pharmacology based on mechanism of action, adverse 627 
effects, and specific activities could be usefully taken into account to better understand the 628 
mechanisms of toxicity of pharmaceuticals and to assess their environmental risk. The next step 629 
in our work is to propose a sound selection of pharmaceuticals to be monitored in surface waters 630 
by implementing a prioritization methodology based on an exposure assessment crossed with a 631 
biological affect assessment using ecotoxicological and pharmacological data. 632 
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Figure 1. Methodology used to calculate Fexcreta values for pharmaceutical compounds and 
active metabolites. As glucuroconjugated metabolites can be cleaved in the environment and 
regenerate the active compound, their excretion rates were taken into account in the calculation of 
the Fexcreta value. 
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Figure 2. Simplified scheme of the different sources of oxazepam. Grey squares indicate an 
active molecule used as a commercialized product; white squares indicate metabolites.  
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Table 1. Consumption, excretion fractions (Fexcreta) and calculated PECs for pharmaceuticals used in France in 2004 (Data from 
AFSSAPS 2006). Active molecules are sorted by decreasing consumption amounts. PEC are calculated using equation 5 and are expressed 
in ng.l-1 . PECA are calculated using actual amounts only. PECB are PECA refined by Fexcreta values. 
Compound name Therapeutic use 
consumption of active 
ingredient in the year 
2004 (kg) 
Fexcreta PECA               (ng.l-1) 
PECB            
(ng.l-1) 
paracetamol analgesic 3303077 0.85 75413 64101 
metformin antihyperglycaemic 716858 1 16367 16367 
troxerutin used in veinous insufficiency 444339 - 10145 - 
aspirin analgesic 396212 - 9046 - 
diosmin used in veinous insufficiency 373544 - 8528 - 
amoxicillin antibiotic 333223 0.9 7608 6847 
ibuprofen anti-inflammatory 240024 0.25 5480 1370 
carbocistein mucolytic 232308 - 5304 - 
sodium valproate anti-epileptic 112162 0.53 2561 1357 
acetylcystein mucolytic 96759 - 2209 - 
fenofibrate lipid regulating 85670 0.01 1956 20 
allopurinol antigout 54247 0.12 1239 149 
dextropropoxyphene analgesic 51963 0.05 1186 59 
buflomedil anti-ischaemic 50958 0.25 1163 291 
naftidrofuryl anti-ischaemic 45523 - 1039 - 
benfluorex lipid regulating 40730 - 930 - 
pristinamycin antibiotic 39855 - 910 - 
naproxen anti-inflammatory 37332 0.7 852 597 
metronidazole antiprotozoal 36545 0.18 834 150 
carbamazepine anti-epileptic 33514 - 765 - 
heptaminol used in orthostatic hypotension 28423 - 649 - 
tramadol analgesic 25897 0.3 591 177 
levodopa management of parkinsonism 24996 - 571 - 
amiodarone anti-arryhtmic 24318 - 555 - 
trimebutine antispasmodic 23550 - 538 - 
clavulanic acid β-lactamase inhibitor 22699 - 518 - 
ketoprofen anti-inflammatory 21697 0.85 495 421 
furosemide diuretic 21288 1 486 486 
bezafibrate lipid regulating 20852 1 476 476 
atenolol anti-hypertensive (β-blocker) 18337 1 419 419 
amphotericin B antifungal 18179 1 415 415 
sulfamethoxazole antibiotic 16730 0.4 382 153 
trimetazidine anti-ischaemic 16480 - 376 - 
clarithromycin antibiotic 15105 0.18 345 62 
ceftriaxone antibiotic 13603 1 311 311 
josamycin antibiotic 12802 0.2 292 58 
propranolol anti-hypertensive (β-blocker) 12487 0.24 285 68 
ciprofloxacin antibiotic 12186 0.5 278 139 
ranitidine anti-ulcer 11656 0.5 266 133 
pravastatin lipid regulating 10969 0.5 250 125 
diclofenac anti-inflammatory 9896 0.15 226 34 
cefpodoxime antibiotic 9283 0.8 212 170 
metoprolol anti-hypertensive (β-blocker) 8786 0.05 201 10 
omeprazole anti-ulcer 8045 0.01 184 1.8 
atorvastatin lipid regulating 7924 0.01 181 1.8 
nicardipine anti-hypertensive  7800 0.01 178 1.8 
simvastatin lipid regulating 6943 0.01 159 1.6 
fosfomycin antibiotic 6774 1 155 155 
hydroxyzine anxiolytic 6638 - 152 - 
doxycycline antibiotic 6243 0.72 143 103 
sertraline serotoninergic anti-depressant  6224 0.14 142 20 
oxazepam anxiolytic 6195 1 141 141 
domperidone antiemetic (dopamine antagonist) 5861 0.07 134 9 
paroxetine serotoninergic anti-depressant  5515 0.03 126 4 
cyamemazine antipsychotic 5441 - 124 - 
pantoprazole anti-ulcer 5287 0.01 121 1 
piperacillin antibiotic 4476 1 102 102 
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Table 1. continued 
Compound name Therapeutic class 
consumption of active 
ingredient in the year 
2004 (kg) 
Fexcreta PECA               (ng.l-1) 
PECB            
(ng.l-1) 
ofloxacin antibiotic 4137 1 94 94 
azithromycin antibiotic 4073 0.5 93 46.5 
phenobarbital anti-epileptic 3915 0.25 89 22.3 
prednisolone corticoid 3743 - 85 - 
fluoxetine serotoninergic anti-depressant  3740 0.1 85 8.5 
citalopram serotoninergic anti-depressant  3487 0.4 80 32 
roxythromycin antibiotic 3404 0.5 78 38.9 
trimethoprim antibiotic 3346 0.5 76 38.2 
zolpidem hypnotic 3344 0.01 76 0.76 
bromazepam anxiolytic 2604 0.03 59 1.78 
mianserine antipsychotic 2423 - 55.3 - 
rifampicine antibiotic  2383 0.18 54 9.8 
prazepam anxiolytic 2166 0.03 49 1.48 
tianeptine antidepressant 2152 0,08 49 3.93 
bisoprolol anti-hypertensive (β-blocker) 2113 0.6 48 28.94 
clorazepate anxiolytic 2109 0.01 48 0.48 
amlodipine anti-hypertensive 2013 0.1 46 4.60 
piroxicam anti-inflammatory 2008 0.1 46 4.58 
zopiclone hypnotic 1948 0.04 44 1.78 
ceftazidime antibiotic 1832 1 42 41,82 
levomepromazine antipsychotic 1699 - 39 - 
prednisone corticoid 1550 - 35 - 
cetirizine anti-allergic 1442 0.7 33 23.05 
fluvoxamine serotoninergic anti-depressant  1121 - 26 - 
glibenclamide antihyperglycaemic 1092 0.1 25 2.49 
baclofen muscle relaxant 1080 0.8 25 19.72 
ramipril antihypertensive 1042 0.02 24 0.48 
loxapine antipsychotic 961 - 22 - 
nadolol anti-hypertensive (β-blocker) 938 1 21 21.42 
loratadine anti allergic 927 - 21 - 
vancomycin antibiotic 918 1 21 20.96 
metoclopramide antiemetic (dopamine antagonist) 913 0.3 21 6.25 
fluconazole antifungal 893 0.8 20 16.30 
lorazepam anxiolytic 585 0.85 13 11.35 
tazobactam β-lactamase inhibitor 560 0.8 13 10.22 
diazepam anxiolytic 526 0.01 12 0.12 
perindopril anti-hypertensive 504 0.1 12 1.15 
hydrocortisone corticoid 453 - 10 - 
oxprenolol anti-hypertensive (β-blocker) 377 0.98 8.60 8.43 
tropatepine management of parkinsonism 355 - 8.11 - 
haloperidol antipsychotic 342 - 7.81 - 
loperamide antidiarrhoeal 318 - 7.26 - 
carvedilol anti-hypertensive (β-blocker) 313 - 7.15 - 
buprenorphine opioid  270 - 6.17 - 
trihexyphenidyle management of parkinsonism 257 - 5.86 - 
nordazepam anxiolytic 237 0.01 5.4 0.05 
alprazolam anxiolytic 178 0.01 4.05 0.04 
terbutaline anti-asthmatic 165 - 3.78 - 
betamethasone corticoid 156 - 3.56 - 
teicoplanin antibiotic 136 1 3.11 3.11 
midazolam hypnotic / amnestic 98 - 2.23 - 
levothyroxin thyroid hormone 59 - 1.34 - 
ondansetron anti-emetic 44 0.1 1.00 0.10 
clonazepam anxiolytic 21 - 0.49 - 
escitalopram serotoninergic anti-depressant  4.6 - 0.11 - 
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ND : no excretion rate value could be determined.  
* Indicates a prodrug.  
** Data from Carlsson et al., 2006. 
Table 2.  Review of phase I metabolites of potential interest for the French aquatic environment. Active metabolites are sorted in alphabetical 
order of parent compounds, except for oxazepam. Underlined metabolites are considered to be of environmental concern (see section about 
environmental relevance of active metabolites for further details). 
Active metabolite Fexcreta Parent   compound Pharmacological activity 
diacetolol 0.5 acebutolol equipotent to parent compound 
oxypurinol ND allopurinol less active than parent compound 
N-desethylamiodarone ND amiodarone equipotent as sodium channel blocker                                                                  less active as antagonist of the calcium channel 
nortryptiline ND amitriptyline active, no further details 
salicylic acid ND aspirin * active, related to the pharmacological effect 
2-hydroxy-atorvastatin ND atorvastatin * active, related to the pharmacological effect 
4-hydroxy-atorvastatin ND atorvastatin * active, related to the pharmacological effect 
β-acid metabolite 0.05 baclofen active, no further details 
10,11-epoxy metabolite ND carbamazepine active, partially responsible for carbamazepine intoxication 
desmethylcarvedilol ND carvedilol 2.5 times more potent in rabbits 
4-OH-phenylcarvedilol ND carvedilol 13 times more potent in rabbits 
4 different metabolites 0.22 (all 
metabolites) ciprofloxacin some metabolites may have an antibacterial activity 
14-OH-clarithromycin 0.15 clarithromycin more active on certain bacterial strains (H influenza), 
synergistic action with clarithromycin 
clofibric acid 0.99 clofibrate * active, linked to the pharmacological effect 
norpropoxyphene 0.25 dextropropoxyphene substantially less central-nervous-system depressant effect than dextro but a greater local anaesthetic effect 
fenofibric acid 0.6 fenofibrate * active, linked to the pharmacological effect 
norfluoxetine 0.2 fluoxetine equipotent to parent compound 
cetirizine ND hydroxyzine active, used as patent medicine 
2-OH-ibuprofen 0.25 iIbuprofen no data on pharmacological activity 
carboxy-ibuprofen 0.37 iIbuprofen no data on pharmacological activity 
desipramine 0.06 imipramine equipotent to parent compound 
OH-metronidazole 0.28 metronidazole between 30 and 50% of the metronidazole activity 
desmethylnaproxen 0.28 naproxen may be pharmacologically inactive 
unidentified metabolites 0.08 norfloxacin some metabolites may have an antibacterial activity 
perindoprilat 0.38 perindopril * active, linked to the pharmacological effect 
4-OH-propranolol ND propranolol equipotent to parent compound 
ramiprilat 0.12 ramipril * 6 times more active than ramipril 
25-O-deacetylrifampicin about 0.5 rifampicin equipotent to parent compound 
ß-OH-acid metabolite 0.55 ** simvastatin * active, linked to the pharmacological effect 
acetylsulfamethoxazole 0.6 sulfamethoxazole no antibacterial activity 
demethyltramadol 0.6 tramadol active, analgesic effect, no further details 
O-desmethylvenlafaxine 0.3 venlafaxine active, no further details 
Zopiclone-N-oxide 0.15 zopiclone less active than parent compound 
1 diazepam 
1 clorazepate 
1 nordazepam 
oxazepam 
ND prazepam 
active, used as a patent anxiolytic                                                    
(see section 3.2) 
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md : median value. 
*: removal fraction determined in winter (Castiglioni et al. 2006). 
**: removal fraction determined in summer (Castiglioni et al. 2006). 
Table 3. Wastewater treatment plants (WWTPs) removal fraction for pharmaceuticals and metabolites 
Wastewater treatment plants removal fraction 
    
  
Ternes 1998 Stumpf et al. 1999 Paxéus 2004 
Bendz et al. 
2005 
Clara et al. 
2005 
Paffoni et al. 
2006 
Castiglioni et al.,         
2006 * 
Castiglioni et al.,           
2006 ** min value max value 
amoxicillin           0.29 0.49 - 1 (md = 0.75) 1 0.29 1 
atenolol   < 0.1   0.52 0 - 0.21 (md = 0.1)  0.36 - 0.76 (md = 0.55) 0 0.76 
azithromycin      0.43    0.43 
bezafibrate 0.83 0.5   0.4 – > 0.9 0.72 0 - 0.66 (md = 0.15) 0 - 0.98 (md = 0.87) 0 0.98 
carbamazepine 0.07  < 0.1 - 0.53 0.3  0.19 0 0 0 0.19 
ciprofloxacin      0.62 0.45 - 0.78 (md = 0.6) 0.53 - 0.69 (md = 0.63) 0.45 0.78 
clarithromycin      0.69 0 - 0.24 (md = 0) 0 0 0.69 
diclofenac 0.69 0.75 < 0.1 - 0.8  0.22  0.27   0.1 0.75 
doxycycline      0.06    0.06 
fenofibrate      > 0.01    > 0.1 
fenofibric acid 0.64 0.45    0.82   0.45 0.82 
furosemide       0 - 0.17 (md = 0.8) 0.15 - 0.62 (md = 0.54) 0 0.62 
ibuprofen 0.09 0.75 0.52 - 0.99  0.96 > 0.9 0.96 0.25 - 0.72 (md = 0.38) 0 - 1 (md = 0.93) 0 1 
OH-ibuprofen    0.95      0.95 
carboxy-ibuprofen    0.96      0.96 
ketoprofen  0.69  0.65  0.93   0.65 0.93 
metoprolol 0.83  < 0.1 - 0.1    0.1   0.1 0.83 
naproxen 0.66 0.78 0.48 – 0.93 0.93  0.88   0.48 0.93 
ofloxacin      0.4 0 - 0.62 (md = 0.43) 0.33 - 0.66 (md = 0.57) 0 0.66 
propranolol 0.96   0.32  0.22   0.22 0.96 
ranitidine       0 - 0.76 (md = 0.39) 0.72 - 0.89 (md = 0.84) 0 0.84 
roxithromycin     0.5 - 0.6 0.51   0.5 0.6 
spiramycine      0.94 0 - 0.11 (md = 0) 0 0 0.94 
sulfamethoxazole     0.5 - 0.6 0.64   0.5 0.64 
trimethoprim   < 0.1 - 0.4  0.49  0.51   0.1 0.51 
vancomycin           1       1 
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ND: not detected in WWTP effluents  
NA: not applicable: carbamazepine Fexcreta values were not determined in this study. 
a: distribution of  PEC calculated using minimal and maximal WWTP removal rates reviewed (see table 3 for 
details) 
b:  PEC calculated using WWTP removal rates calculated by Paffoni et al., 2006. 
*: PECc are considered negligible considering the very low Fexcreta values of 0.01 assumed for diazepam and 
simvastatin. 
**: PECc is considered negligible as Paffoni et al. (2006) reports a WWTP removal fraction of 1. 
WWTP measured concentrations from Paffoni et al. (2006) are mean concentrations.
 
 
 
 
 
 
 
 
Table 4. Comparison of calculated PEC for wastewater treatment plants (WWTP) effluents with field measurements conducted in France. 
PEC are determined using equation (5) and are expressed in ng.l-1. 
  
Pharmaceutical concentrations in French WWTP effluents (ng.l-1) Calculated PEC for WWTP effluents 
 
Paffoni et al. 
2006 
Miège et al. 
2006 
Andreozzi et al. 
2003 Rabiet et al. 2006 PECC (ng.l
-1) a PECC (ng.l-1) b 
amoxicillin 40       0 - 48615 48615 
atenolol 570     1000 - 4190 2010 
azithromycin 101       260 
bezafibrate 840  ND - 1070   95 - 4760 1330 
carbamazepine 1020  980 - 1200 157 - 293 NA NA 
ciprofloxacin 101  60   305 - 765 530 
clarithromycin 117     190 - 620 190 
diazepam ND    ND negligible * negligible * 
diclofenac 810  250 - 410 211 - 486 85 - 305 250 
doxycycline 73       965 
fenofibrate 310  20 - 120     < 180 
ibuprofen 600  20 - 1820 18 - 219 0 - 13700 550 
ketoprofen 270  ND - 1620 22 - 1081 295 - 1475 295 
metoprolol 100 509 - 1774 80   15 - 90 90 
naproxen 350  510 - 1730 42 - 289 420 - 3100 715 
ofloxacin 177  330 - 510   320 - 940 565 
propranolol 190 416 - 1111    25 - 535 535 
roxithromycin 50     155 - 195 190 
simvastatin ND     negligible * negligible * 
sulfamethoxazole 205  70 - 90   550 - 765 550 
trimethoprime 72  20 - 40   185 - 345 185 
vancomycin ND        negligible ** 
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PEC values were calculated using equation 5. Sample and references report to measured concentrations. 
All PECs are calculated for surface waters except the PEC for fenofibric acid which is calculated for WWTP 
effluents. 
*: active metabolite of simvastatin. 
a: mean values.  
b: median values. 
c: oxazepam PEC was calculated by summing different sources for this compound. 
ND: not detected or not already searched in the aquatic environment.  
NA: not applicable due to lack of data.  
Table 5. Calculated surface water PEC values for relevant metabolites.  
Metabolite PECB (ng.l-1) PECC (ng.l-1) measured concentration sample reference 
salicylic acid NA NA 25 surface water Ternes, 1998 
161a WWTP effluent 
acetylsulfamethoxazole 230 NA 
70 a downstream WWTP 
Ashton et al. 2004 
50 WWTP effluent 
hydroxy-ibuprofen 1370 70 20 downstream WWTP 
430 WWTP effluent 
carboxy-ibuprofen
 
2025 100 
230 downstream WWTP 
Bendz et al. 2005 
14-OH-clarithromycin 50 NA ND - - 
OH-metronidazole 235 NA ND - - 
25-O-deacetyl-rifampicin 25 NA ND - - 
norfluoxetine 17 NA ND - - 
oxazepam 
 205c NA 1500 surface water Togola et al., 2007 
zopiclone N-oxide 7 NA ND - - 
norpropoxyphene 295 NA ND - - 
demethyltramadol 355 NA ND - - 
β-OH-acid metabolite * 90 NA ND - - 
1260 a WWTP effluent Paffoni et al. 2006 
380 b WWTP effluent fenofibric acid 1175 2068 
45 b surface water 
Ternes, 1998 
perindoprilat 4 NA ND - - 
ramiprilat 3 NA ND - - 
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AF: Assessment Factor. 
Taxa species and references refer to the assay that showed the lowest NOEC. 
* Indicates that risk quotients for these compounds were calculated applying the EMEA methodology (three NOEC values from three different taxonomic 
groups). Other risk ratios were conducted using TGD (2003) recommendations (with only one or two NOEC values). When three NOEC values for three 
different taxonomic groups were available, a factor of 10 was applied to the lowest NOEC value; when two NOECs were available, a factor of 50 was 
applied; a factor of 100 was applied when only one NOEC value was available.  
** Quoted by Webb 2001, in Kummerer 2001.  
ND: not determined. 
Table 6. Determination of risk quotients for pharmaceutical compounds (compounds are sorted by decreasing risk ratios values). 
compound most sensible specie taxa endpoint reference of the 
ecotoxicological assay AF used 
PNEC final 
value                    
(ng.l-1) 
PECA value       
(ng.l-1) 
PECB value       
(ng.l-1) 
PECC value       
(ng.l-1) 
PEC/PNEC  
ratio 
amoxicillin S. leopoliensis cyanobacteria growth Andreozzi et al. 2004 10 * 78   4860 62.3 
aspirin Daphnia. magna cladoceran reproduction Marques et al. 2004 100 10000 9046   0.9 
ofloxacin S. leopoliensis cyanobacteria growth Ferrari et al. 2004 50 100   56.5 0.56 
propranolol Hyallela azteca gammaridae reproduction Huggett et al. 2002 10 * 100   54.5 0.54 
carbamazepine Ceriodaphnia dubia cladoceran reproduction Ferrari et al. 2004 10 * 2500 765   0.31 
furosemide Ceriodaphnia. dubia cladoceran reproduction Isidori et al. 2006 100 1560  486  0.31 
clarithromycin D. magna cladoceran reproduction Yamashita et al. 2006 50 62   19 0.3 
diclofenac Ceriodaphnia dubia cladoceran reproduction Ferrari et al. 2004 10 * 100   25 0.25 
sertraline Ceriodaphnia. dubia cladoceran reproduction Henry et al. 2003 100 90  20  0.22 
sulfamethoxazole S. leopoliensis cyanobacteria growth Ferrari et al. 2004 10 * 590   55 0.1 
fluoxetine unspecified chlorophyceae growth FDA-CDER 1996 10 * 100  9  0.09 
fenofibrate Daphnia. magna cladoceran reproduction Garric et al. 2006 50 140   < 18 < 0.13 
paroxetine Ceriodaphnia. dubia cladoceran reproduction Garric et al. 2006 50 600  4  6.67 10-3 
fluvoxamine Ceriodaphnia. dubia cladoceran reproduction Henry et al. 2004 50 7400 26   3.5 10-3 
citalopram Ceriodaphnia. dubia cladoceran reproduction Henry et al. 2003 100 8000  32  4 10-3 
ibuprofen Daphnia.magna cladoceran reproduction Han et al. 2006 100 2. 10 5   55 2.7 10-4 
trimethoprim S. capricornutum chlorophyceae growth Eguchi et al. 2004 100 2,55. 10 5   19 7.45 10-5 
acebutolol Ceriodaphnia dubia cladoceran reproduction Garric et al. 2006 50 1,25. 10 6 NA NA NA NA 
erythromycin S. capricornutum chlorophyceae growth Eguchi et al. 2004 50 206 NA NA NA NA 
clofibric acid Ceriodaphnia dubia cladoceran reproduction Ferrari et al. 2004 10 * 64 negligible negligible negligible negligible 
clofibrate Daphnia.magna cladoceran reproduction Köpf 1995 *** 50 200 negligible negligible negligible negligible 
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